Acumen Pharmaceuticals Inc [ABOS] stock is trading at $2.16, down -0.46%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABOS shares have gain 5.37% over the last week, with a monthly amount glided 27.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acumen Pharmaceuticals Inc [NASDAQ: ABOS] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $4. Previously, Citigroup started tracking the stock with Buy rating on July 26, 2024, and set its price target to $7. On December 12, 2023, Deutsche Bank initiated with a Buy rating and assigned a price target of $8 on the stock. Cantor Fitzgerald initiated its recommendation with an Overweight and recommended $13 as its price target on May 18, 2023. BTIG Research started tracking with a Buy rating for this stock on July 15, 2022, and assigned it a price target of $15. In a note dated June 30, 2022, H.C. Wainwright initiated a Buy rating and provided a target price of $15 on this stock.
Acumen Pharmaceuticals Inc [ABOS] stock has fluctuated between $0.86 and $2.46 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Acumen Pharmaceuticals Inc [NASDAQ: ABOS] shares were valued at $2.16 at the most recent close of the market. An investor can expect a potential return of 224.07% based on the average ABOS price forecast.
Analyzing the ABOS fundamentals
Gross Profit Margin for this corporation currently stands at -0.02% with Operating Profit Margin at -776.57%, Pretax Profit Margin comes in at -749.16%, and Net Profit Margin reading is -749.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -0.97 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.13 points at the first support level, and at 2.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.19, and for the 2nd resistance point, it is at 2.21.
Ratios To Look Out For
For context, Acumen Pharmaceuticals Inc’s Current Ratio is 6.02. As well, the Quick Ratio is 6.02, while the Cash Ratio is 2.13.
Transactions by insiders
Recent insider trading involved Zuga Matt, CFO & Chief Business Officer, that happened on Jan 23 ’25 when 28902.0 shares were sold. CFO & Chief Business Officer, Zuga Matt completed a deal on Jan 21 ’25 to sell 4364.0 shares. Meanwhile, Chief Executive Officer OConnell Daniel Joseph sold 12619.0 shares on Jan 21 ’25.
